Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., have entered into a definitive agreement to acquire all outstanding shares of Akcea stock it does not already own, approximately 24%, in a cash transaction valued at approximately $500 million. The transaction has been approved by the Ionis and Akcea Boards. “This acquisition is another step forward in Ionis’ evolution and creates a stronger, more efficient organization to the benefit of all stakeholders,&#822...